Exelixis, Pharmacia deal

EXEL received a milestone payment under its 1999 deal with PHA triggered by EXEL's delivery of two targets for Alzheimer's disease or Metabolic Syndrome (see BioCentury, Feb. 14 and March 8, 1999). ...